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Nasopharyngeal carcinoma (NPC) is the most familiar cancer originating in the nasopharynx, and not
uncommonly found in the head and neck region in adults. Under appropriate and effective treatment,
the outcome subsequent to medical intervention can be relatively good in adults with nasopharyngeal
carcinoma. However, NPC is very uncommon in children younger than 10 years, and its incidence
increases gradually with patient age. In general, NPC may be more aggressive in character, with
frequent distant metastasis while initial diagnosis in children. We reported the case of a 12-year-old
girl with advanced nasopharyngeal carcinoma, who was refractory to multiple chemotherapy regi-
mens. We herein have provided a summary review of the literature regarding the incidence, char-
acteristics, treatment and outcome of nasopharyngeal carcinoma in children, in the hopes of
encouraging further investigations that will create additional treatment options for those who suffer
NPR at any age.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nasopharyngeal carcinoma (NPC) is a tumor arising from the
epithelial cells that line the surface of the nasopharynx. It is a
commonly found tumor of the head and neck region in adults, and
its incidence varies widely in different regions. It has been observed
that high risk areas for NPC include areas such as Southern China,
Hong Kong, and Taiwan. Regardless of the region, however, NPC is
exceedingly rare in children. An estimated 5% of primary malignant
tumors in children originate in the area of the head and neck,1
while nasopharyngeal carcinoma constitutes about 2% of head
and neck malignant tumors in children.2 Also, NPC in children
differs from its adult counterpart in the prevalence of the non-
keratinizing undifferentiated subtype, a histologic pattern associ-
ated with advanced locoregional spread and frequent distant me-
tastases. The standard therapy for children with NPC has generally
followed the guidelines that have been established for adults. Here
we reported a 12-year-old girl with advanced and metastaticnd Oncology, Department of
ospital, College of Medicine,
d, Tainan 704, Taiwan.
).
ncology Society.
Society. Production and hosting bynasopharyngeal carcinoma, and refractory to multiple treatment
regimens, who ultimately expired 1 year after diagnosis.2. Case report
A 12-year-old girl had normal developmental milestones, and
further lacked any indication of abuse, alcohol consumption or
contact history with smoking. She complained of right neck
swelling for 1 week in May, 2014. Her associated symptoms
included poor appetite, trismus, and right neck pain. The patient
was treated with antibiotics initially, but the intervention was un-
successful.We undertook further examination byway of a head and
neck CT scan, which revealed a huge nasopharyngeal tumor,
approximately 6 cm in size, with locally advanced extension and
invasion. Furthermore, bilateral neck lymphadenopathy was also
noticed (Fig. 1A, B). Under the guidance of a Karl Storz telescope,
one granular mass was noted over the posterior nasopharyngeal
wall, which encroached to the right fossa of Rosenmuller fossa and
torus tubarius. The ﬁnal histological examination conﬁrmed the
diagnosis of nasopharyngeal carcinoma, undifferentiated (WHO
type 3) (Fig. 2). The patient's EBV viral load was checked and
determined to be 1.09  103 copies/mL. Ultimately, we assessed
that the patient was clinical stage T4N2M0, and stage IVA. Deﬁni-
tive CCRT was indicated.Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Image of the Head and neck CT reveals (A) a huge nasopharyngeal tumor extending to the skull base; (B) enlarged neck lymphadenopathy. After treatment (CCRT), follow-up
head and neck CT reveals shrinkage in size of the primary nasopharyngeal tumor (C), and bilateral neck lymphadenopathy (D).
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received weekly Cisplatin (30 mg/m2) and concurrent radiotherapy
over the nasopharyngeal tumor and gross lymph nodes (7380 cGy/
41 fractions), which was completed in August, 2014. A follow-up
head and neck CT revealed shrinkage in size of the nasopharyn-
geal tumor and lymph nodes (Fig. 1C, D). However, multiple hepatic
nodules were incidentally discovered during follow-up. Addition-
ally, she also had unexplained simultaneous abnormal hemogram.
Nasopharyngeal carcinoma with liver and bone marrowmetastasis
was subsequently conﬁrmed after liver biopsy and bone marrow
study (Figs. 3 and 4).
To address the patient's metastatic nasopharyngeal carcinoma,
she had received multiple treatment regimens, even including
target therapy with cetuximab. Although the primary nasopha-
ryngeal tumor was still in stable disease status, her condition of
distal metastases progressively deteriorated. The patient was
informed as to her poor prognosis concerning ongoing efforts to
treat her refractory metastatic nasopharyngeal carcinoma, and she
was soon under palliative care. Later, the patient passed in June,
2015.3. Discussion
Nasopharyngeal carcinoma (NPC) is the predominant tumor
type arising in the nasopharynx. The etiology of this challenging
disease is multifactorial and involves virological, environmental,
and genetic components. The incidence of nasopharyngeal carci-
noma demonstrates a marked geographical variation. In general,
the incidence of nasopharyngeal carcinoma increases with age,
peaking at around 50e59 years of age, with a early small peak
found in late childhood in some populations.3 Childhood naso-
pharyngeal carcinoma, less than 1% of all childhood malignant tu-
mors, is a very rare disease.
Nasopharyngeal carcinoma commonly presents as nosebleeds,
nasal congestion and obstruction, or otitis media. Given the rich
lymphatic drainage of the nasopharynx, bilateral cervical lymph-
adenopathies are often the ﬁrst sign of disease. Three histological
subtypes are recognized by the World Health Organization (WHO):
1) keratinizing squamous cell carcinoma (type 1); 2) non-
keratinizing squamous cell carcinoma (type 2); and 3) undifferen-
tiated carcinoma (type 3). The type 3 nasopharyngeal carcinoma is
Fig. 2. Nasopharynx. The nasopharyngeal tissue is inﬁltrated by sheets and fascicles of spindle-shaped neoplastic cells. Special stain of cytokeratin and EBER-1 in situ hybridization
are positive (A) H&E, 100x; (B) H&E, 400x; (C) cytokeratin; (D) EBER-1.
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cancerous cells, and has a high rate of distant metastases, usually
including the bones, lungs, and liver. However, bone marrow
metastasis remains a rare condition, which can have a noticeably
adverse effect on patient survival duration. Zen et al retrospectively
reviewed 23 patients with recurrent nasopharyngeal carcinoma.
Five of the subjects were diagnosed to have bone marrow metas-
tasis, which had developed 4e24 months after aggressive treat-
ment. The clinical features of such metastasis were anemia,
leukopenia, thrombocytopenia, sepsis, tenderness of the sternum,
and fever. All ﬁve patients had advanced local-regional disease, and
suffered a rapid downhill course after the diagnosis of bone
marrow metastasis.4
Sultan et al5 retrospectively searched the surveillance, epide-
miology, and end results (SEER) database for patients who were
diagnosed with NPC from 1988 to 2006. They compared the clinical
features and outcomes of 129 children and adolescents (<20 years
of age) and 5885 adults. Younger patients had distinct features with
advanced stages more frequently observed (of the combined chil-
dren and adolescents, 31% and 46% had stages III and IV, respec-
tively) and 87% had WHO type III histology. Since there is a strongassociation between the histology of undifferentiated carcinoma,
Epstein-Barr virus infection,6 and the high rate of advanced disease
status, nasopharyngeal carcinoma in children is distinguishable
from the adult form by its close association with Epstein-Barr virus
(EBV) infection, a higher rate of undifferentiated histology, and a
greater incidence of advanced locoregional disease.7 Despite an
elevated incidence of advanced loco-regional disease in children
and young adults compared with older adults with nasopharyngeal
carcinoma, the overall survival rates are not signiﬁcantly different
between these population groups. Several studies have found that
children and adolescent NPC patients have superior results
comparedwith adult NPC patients, with 5-year overall survival (OS)
rate 71% v 58%, respectively (p ¼ 0.03).8
Standard therapy for NPC in children has generally followed the
guidelines established for adults. Since undifferentiated NPC is very
sensitive to radiation, high dose radiation to the nasopharynx and
involved cervical nodal regions is the mainstay of treatment of
locoregional NPC. However, this treatment appears to control the
primary tumor, but shows no beneﬁt for preventing the appearance
of distant metastasis. The prognosis of childrenwith advanced NPC
(Stages III and IV) treated with radiation therapy alone is poor, with
Fig. 3. Liver. Liver tissue is inﬁltrated by sheets and fascicles of spindle-shaped neoplastic cells, which are positive for EBER-1. (A) H&E, 20x; (2) H&E, 200x; (C) H&E, 400x; (D) and
EBER-1.
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radiotherapy-related morbidities in children are also a great
concern among long-term survivors, including xerostomia, hearing
loss, neck ﬁbrosis, hypothyroidism, and the most troubling, second
primary malignancy in the radiation ﬁeld.10 The poor overall sur-
vival and high incidence of systemic failure in patients with locally
advanced NPC has led to the investigation of early combined
therapy (chemotherapy before, concurrently with, or after radio-
therapy) to improve survival in childhood NPC. Single-agent studies
have shown that adriamycin, epirubicin, cisplatin, and bleomycin
are the most active agents for treatment of NPC.11 Unfortunately,
due to the small sample sizes of childhood nasopharyngeal carci-
noma, the standard chemotherapy combinations or treatment
schedules are not available. Platinum-based chemotherapy has
gained popularity, however, including BEP (Bleomycin, Epirubicin,
Cisplatin), PF (Cisplatin, Fluorouracil), MPF (Methotrexate,
Cisplatin, Fluorouracil), and PMB (Cisplatin, Methotrexate, Bleo-
mycin). According to data from different studies, the survival rate
was around 40e90% when a combination of different chemo-
therapy regimens and radiotherapy are utilized.12e15
The interval between a patient's initial treatment and recurrence
is an important determinant of outcome. Although cure rates in
childhood NPC have improvedwith recent advances in radiotherapy,and the use of neoadjuvant or adjuvant chemotherapy, around
20e50% of patients still suffer from recurrent or metastatic disease.
These observations suggest that more effective chemotherapy is
needed for metastatic NPC. Trials of several chemotherapy regimens
have beendone in adults and in childrenwith recurrent ormetastatic
disease, but there have not been sufﬁcient results reported that could
conﬁdently add any new regimen to existing treatment options.
4. Conclusions
In conclusion, childhood nasopharyngeal carcinoma is very rare,
but presents with a greater incidence of advanced locoregional
disease. On the basis of the biology of NPC, it is clear that early
administration of an effective chemotherapeutic agent is needed
for treatment of childhood NPC. Platinum-based chemotherapy
combined with radiotherapy, is the standard therapy. However,
local recurrence or distant metastases may occur, which adversely
affects patient survival. In long-term follow-up, treatment-related
morbidity and second primary malignancy are routinely
observed. Conclusive data on the standard of care for childhood
NPC must be collected from cooperating group studies so that new
strategies can be designed for the development of more effective
and less toxic treatments and preventive agents.
Fig. 4. Bone marrow. The bony trabeculae and marrow space are inﬁltrated by tumor cells, highlighted by cytokeratin. EBER-1 in situ hybridization is positive. (A) H&E, 20x;
(B) H&E, 200x; (C) Cytokeratin; (D) EB ER-1.
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